COST-EFFECTIVENESS-ANALYSIS AND THE CONCEPT OF QUALITY ADJUSTED LIFE YEAR (QALY) IN ROMANIA .
SORIN PAVELIU1*, CIPRIAN-PAUL RADU2, FLORIN TUDOSE3, CATALINA TUDOSE4, ANDREEA LETITIA ARSENE4
1Titu Maiorescu University, Faculty of Medicine and Dental Medicine, Bucharest, Romania
2National School of Public Health, Management and Development in the Medical Field, Romania
3Clinical Universitary Emergency Hospital Bucharest, Romania
4Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
*corresponding author: sorinpaveliu@yahoo.com
Download Full Article

Abstract:

The article presents the Romanian status regarding the use of indicators like quality-adjusted life years in the decision making process at the level of the health care system, presenting also some ideas for the improvement of the actual situation, for the patient’s benefits.
The authors analysed the literature covering the pharmacoeconomics and the quality-adjusted life years and they performed a Romanian legislation review covering the health insurance, resources allocation, national health programs and the drugs market.
Romania took a step forward by demanding pharmacoeconomic data for the decision regarding the free-of-charge drugs or the ones with co-payment from the patients. But there are several barriers which block the effective utilization of pharmacoeconomic studies in the decision making and management: the lack of regulations regarding the development of pharmaeconomic studies, the lack of national guidelines for the authors, the lack of a central agency for Health Technology Assessment. Moreover, Romania has a great problem regarding the calculation of the real cost for the diseases, and this represents also a major barrier for the process of pharmacoeconomic studies standardization.
Romania has to adopt quickly resource allocation criteria based also on the economic deficiency of the health interventions. The use of pharmacoeconomics studies for resources allocation could support the improvement of the health budget.

Top